This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Mayo Clinic
Massive Bio, Inc.
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Shattuck Labs, Inc.
Checkpoint Therapeutics, Inc.
RAPT Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Incyte Corporation
MultiVir, Inc.
Hoffmann-La Roche